Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate the Safety and the Efficacy of a Blinatumomab Based Consolidation and Maintenance in Patients With High-risk B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). GRAALL-QUEST

Trial Profile

A Phase II Study to Evaluate the Safety and the Efficacy of a Blinatumomab Based Consolidation and Maintenance in Patients With High-risk B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). GRAALL-QUEST

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms Graall-2014-QUEST; GRAALL-QUEST
  • Most Recent Events

    • 12 Dec 2023 Results identifying patient- and disease-related factors associated with response to BLIN, and to understand how BLIN influences the outcome after allo-HSCT, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Primary endpoint (Disease Free Survival Y3) has been met, as per results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 13 Dec 2022 Results (n=489; Between December 2015 and December 2020) comparing (QUEST cohort (n=93) was compared to the control cohort (n=104)) their outcome to that of similar patients treated in the same GRAALL-2014/B trial but without frontline blinatumomab, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top